GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (FRA:2CV) » Definitions » Effective Interest Rate on Debt %

ConvaTec Group (FRA:2CV) Effective Interest Rate on Debt % : 5.45% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ConvaTec Group Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. ConvaTec Group's annualized positive value of Interest Expense for the quarter that ended in Jun. 2024 was €69 Mil. ConvaTec Group's average total debt for the quarter that ended in Jun. 2024 was €1,258 Mil. Therefore, ConvaTec Group's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2024 was 5.45%.


ConvaTec Group Effective Interest Rate on Debt % Historical Data

The historical data trend for ConvaTec Group's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group Effective Interest Rate on Debt % Chart

ConvaTec Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.01 2.70 2.52 3.71 5.53

ConvaTec Group Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.16 2.95 4.64 5.87 5.45

Competitive Comparison of ConvaTec Group's Effective Interest Rate on Debt %

For the Medical Instruments & Supplies subindustry, ConvaTec Group's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ConvaTec Group's Effective Interest Rate on Debt % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ConvaTec Group's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where ConvaTec Group's Effective Interest Rate on Debt % falls into.



ConvaTec Group Effective Interest Rate on Debt % Calculation

ConvaTec Group's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -67.216/( (1227.389+1203.471)/ 2 )
=-1  *  -67.216/1215.43
=5.53 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1208.226 + 19.163
=1227.389

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1184.489 + 18.982
=1203.471

ConvaTec Group's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Jun. 2024 ))/ count )
=-1  *  -68.56/( (1203.471+1311.655)/ 2 )
=-1  *  -68.56/1257.563
=5.45 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1184.489 + 18.982
=1203.471

Total Debt  (Q: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1292.239 + 19.416
=1311.655

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Jun. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


ConvaTec Group  (FRA:2CV) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


ConvaTec Group Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


ConvaTec Group Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, 7th Floor, Paddington, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.

ConvaTec Group Headlines

No Headlines